



# ***Alpa Laboratories Ltd.***

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

14<sup>th</sup> February, 2022

To,  
Listing Department,  
BSE Limited.  
Rotunda Building, P J Towers  
Dalal Street, Fort,  
Mumbai – 400 001  
Scrip Code: 532878

To,  
Listing Department,  
National Stock Exchange of India Limited.  
'Exchange Plaza', C-1, Block G,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Scrip Code: ALPA

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This is with reference to our letter dated 01<sup>st</sup> February, 2022 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for Quarter ended on 31<sup>st</sup> December, 2021 with Limited Review Report from the Statutory Auditor of the Company.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

**For ALPA LABORATORIES LIMITED**

Swati Bagh  
Company Secretary

**ALPA LABORATORIES LIMITED**

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

**Financial Results for Quarter ended 31st December 2021**

(Rs. in lacs except EPS)

**I. Statement of Profit and Loss - Standalone and Consolidated**

Particular	STANDALONE RESULTS					
	Quarter Ended		Nine months Ended			Year Ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
	Unaudited					Audited
<b>1. Income</b>						
a) Revenue from operations	2,932.84	2,625.50	3,316.42	8,676.61	7,256.67	9,755.42
b) Other Income	220.12	269.78	117.80	707.39	376.95	441.07
<b>1. Total income from operations (net) (a+b)</b>	<b>3,152.96</b>	<b>2,895.28</b>	<b>3,434.22</b>	<b>9,384.00</b>	<b>7,633.62</b>	<b>10,196.49</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	1,554.37	1,745.83	1,498.60	4,830.30	3,939.51	5,422.74
b) Purchases of stock-in-trade	169.23	136.00	80.99	466.24	361.14	639.12
c) Changes in inventories of finished products, work in progress and stock in trade	101.82	(293.68)	406.37	28.69	22.30	(115.29)
d) Employee benefit expenses	287.09	288.25	372.67	863.82	899.36	1,174.51
e) Finance costs	8.38	6.03	2.55	17.45	8.32	9.82
f) Depreciation and amortization expenses	43.32	42.01	30.65	115.99	87.73	122.87
g) Other expenses						
Manufacturing & Operating	122.77	174.54	134.31	420.93	353.25	528.98
Others	325.18	221.69	530.88	862.14	1,032.98	1,334.51
<b>Total expenses</b>	<b>2,612.16</b>	<b>2,320.67</b>	<b>3,057.02</b>	<b>7,605.56</b>	<b>6,704.59</b>	<b>9,117.26</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>540.80</b>	<b>574.61</b>	<b>377.20</b>	<b>1,778.44</b>	<b>929.03</b>	<b>1,079.23</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>540.80</b>	<b>574.61</b>	<b>377.20</b>	<b>1,778.44</b>	<b>929.03</b>	<b>1,079.23</b>
<b>6. Tax (Expenses)/ Benefit</b>						
Current tax	-	-	-	-	-	(250.00)
Deffered tax	-	-	-	-	-	114.19
Tax Related to Earlier Years	-	-	-	-	-	11.40
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>540.80</b>	<b>574.61</b>	<b>377.20</b>	<b>1,778.44</b>	<b>929.03</b>	<b>726.44</b>
<b>8. Other Comprehensive Income</b>						
(i) (a) Items that will not be reclassified to profit or loss	0.43	0.08	0.55	0.57	0.55	2.17
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other comprehensive (loss)/ income (net of tax)</b>	<b>0.43</b>	<b>0.08</b>	<b>0.55</b>	<b>0.57</b>	<b>0.55</b>	<b>2.17</b>
<b>9. Total comprehensive income for the period (7+8)</b>	<b>541.24</b>	<b>574.69</b>	<b>377.75</b>	<b>1,779.01</b>	<b>929.58</b>	<b>728.61</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity ( excluding revaluation reserve)</b>	-	-	-	-	-	9,647.51
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>2.57</b>	<b>2.73</b>	<b>1.80</b>	<b>8.46</b>	<b>4.42</b>	<b>3.46</b>

**Notes -**

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies ( Indian accounting Standards) Rules, 2015 and Companies ( Indian Accounting Standards ) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- The outbreak of corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. During the quarter ended December 31, 2021, there is no significant impact on the operations of the Company.

For ALPA LABORATORIES LIMITED

  
**PARASH CHAWLA**  
 MANAGING DIRECTOR  
 DIN NO.00520411





**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE SEBI LODR REGULATIONS, 2015 (AS AMENDED)**

To the Board of Directors of **ALPA LABORATORIES LIMITED,**

1. I have reviewed the accompanying statement of unaudited financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **31<sup>st</sup> December, 2021**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the accounting principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013('the Act'), and other accounting principles accepted in India. My responsibility is to express a conclusion on the Statement based on my review.
3. I conducted my review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. I have not performed an audit and accordingly, I do not express an audit opinion.
4. Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Anuradha Ratnaparkhi & Associates.**

Chartered Accountants

Firm Registration No.023451C

**Anuradha Ratnaparkhi**

Proprietor

Membership Number: 075412

UDIN: 22075412ACCBB07995

Date: 14<sup>th</sup> Day of February, 2022

Place: Indore



**ALPA LABORATORIES LIMITED**

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

**I. Statement of Profit and Loss - Standalone and Consolidated**

(Rs. in lacs except EPS)

Particular	CONSOLIDATED RESULTS					
	Quarter Ended			Nine months Ended		Year Ended
	31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
	Unaudited					Audited
<b>1. Income</b>						
a) Revenue from operations	2,932.84	2,625.50	3,316.42	8,710.28	7,256.67	9,755.42
b) Other Income	220.12	266.84	112.83	913.82	373.35	439.62
<b>1. Total income from operations (net) (a+b)</b>	<b>3,152.96</b>	<b>2,892.34</b>	<b>3,429.25</b>	<b>9,624.10</b>	<b>7,630.02</b>	<b>10,195.04</b>
<b>2. Expenses</b>						
a) Cost of materials consumed	1,554.37	1,745.83	1,498.60	5,040.52	3,939.51	5,422.74
b) Purchases of stock-in-trade	169.23	136.00	80.99	466.24	361.14	639.12
c) Changes in inventories of finished products, work in progress and stock in trade	101.82	(293.68)	406.37	60.63	22.30	(115.29)
d) Employee benefit expenses	287.09	288.25	372.67	863.34	899.36	1,174.51
e) Finance costs	8.38	6.20	1.81	18.86	6.95	7.79
f) Depreciation and amortization expenses	43.32	42.01	30.65	115.92	87.73	122.87
g) Other expenses						
Manufacturing & Operating	122.77	174.54	134.31	425.37	353.25	528.98
Others	325.18	221.69	530.88	875.06	1,032.99	1,335.67
<b>Total expenses</b>	<b>2,612.16</b>	<b>2,320.84</b>	<b>3,056.28</b>	<b>7,865.94</b>	<b>6,703.23</b>	<b>9,116.39</b>
<b>3. Profit/(Loss) before exceptional items and tax (1-2)</b>	<b>540.80</b>	<b>571.50</b>	<b>372.97</b>	<b>1,758.16</b>	<b>926.79</b>	<b>1,078.65</b>
<b>4. Exceptional Items</b>	-	-	-	-	-	-
<b>5. Profit/ Loss(-) before tax (3+/-4)</b>	<b>540.80</b>	<b>571.50</b>	<b>372.97</b>	<b>1,758.16</b>	<b>926.79</b>	<b>1,078.65</b>
<b>6. Tax (Expenses)/ Benefit</b>						
Current tax	-	-	-	-	-	(250.00)
Deffered tax	-	-	-	-	-	(114.19)
Tax Related to Earlier Years	-	0.15	-	0.15	0.15	10.25
<b>7. Profit/ Loss(-) for the period (5-/+6)</b>	<b>540.80</b>	<b>571.65</b>	<b>372.97</b>	<b>1,758.31</b>	<b>926.94</b>	<b>724.71</b>
<b>8. Other Comprehensive Income</b>						
(i) (a) Items that will not be reclassified to profit or loss	0.43	1.68	-	1.00	1.04	2.17
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
<b>Total Other comprehensive (loss)/ income (net of tax)</b>	<b>0.43</b>	<b>1.68</b>	<b>-</b>	<b>1.00</b>	<b>1.04</b>	<b>2.17</b>
<b>9. Total comprehensive income for the period (7+8)</b>	<b>541.24</b>	<b>573.33</b>	<b>372.97</b>	<b>1,759.32</b>	<b>927.98</b>	<b>726.88</b>
<b>10. Paid-up equity share capital (Face Value Rs. 10 Each)</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>	<b>2,104.06</b>
<b>11. Other equity (excluding revaluation reserve)</b>	-	-	-	-	-	8,660.08
<b>12. Debenture Redemption Reserve</b>	-	-	-	-	-	-
<b>13. Basic and Diluted Earnings per share after extraordinary items (not annualized)</b>	<b>2.57</b>	<b>2.72</b>	<b>1.77</b>	<b>8.36</b>	<b>4.41</b>	<b>3.45</b>

**Notes -**

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies ( Indian accounting Standards) Rules, 2015 and Companies ( Indian Accounting Standards ) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- The outbreak of corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. During the quarter ended December 31, 2021, there is no significant impact on the operations of the Group.

For ALPA LABORATORIES LIMITED

*(Signature)*  
**PARESH CHAWLA**  
**MANAGING DIRECTOR**  
**DIN NO.00520411**





**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE SEBI LODR REGULATIONS, 2015 (AS AMENDED)**

To the Board of Directors of **ALPA LABORATORIES LIMITED,**

1. I have reviewed the accompanying statement of unaudited financial results of **ALPA LABORATORIES LIMITED** (The Holding Company) and its Subsidiary (refer Annexure1 for the list of subsidiaries included in the Statement) for the quarter ended **31<sup>st</sup> December 2021** being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the accounting principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles accepted in India. My responsibility is to express a conclusion on the Statement based on my review.
3. I conducted my review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. I have not performed an audit and accordingly, I do not express an audit opinion.  
  
I also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March, 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations (As amended), to the extent applicable.
4. Based on my review conducted, nothing has come to my attention that causes me to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.





**Anuradha Ratnaparkhi & Associates**

CHARTERED ACCOUNTANTS

**Anuradha Ratnaparkhi**

M.com., FCA



9D, Sampat Farms, Survey No. 15/26,  
Opp. Agrawal Public School,  
Bicholi Mardana Road, Indore 452 016 (M.P.)  
Tel. : +91 731-4979244, M : +91 98934-62644  
E-mail : associate@caanuradha.co.in

5. The consolidated unaudited quarterly financial results also include the subsidiary's share of net Loss (including other comprehensive income) (before eliminating intercompany transactions) amounting to ₹ 443 for the quarter ended 31<sup>th</sup> December, 2021 as considered in the consolidated financial results, whose financial information has not been audited by me. These financial information are unaudited and have been furnished to me by the management duly certified by them and my opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this associate, and my report in terms of Regulation 33 read with Regulation 63 of the SEBI {Listing Obligations and Disclosure Requirements} Regulations, 2015 read with SEBI Circular CIR/CFD/FAC/62/2016 dated 5 July 2016, in so far as it relates to the aforesaid subsidiary, are based solely on such unaudited financial information. In my opinion and according to the information and explanations given to me by the management this financial information is not material to the Group.

My opinion on the consolidated financial results is not modified in respect of this matter with respect to my reliance on the financial information certified by the management.

**For Anuradha Ratnaparkhi & Associates.**

Chartered Accountants

Firm Registration No.023451C

**Anuradha Ratnaparkhi**

Proprietor

Membership Number: 075412

UDIN: 22075412ACCIET6255

Date: 14<sup>th</sup> Day of February, 2022

Place: Indore

**Anuradha Ratnaparkhi & Associates**

**CHARTERED ACCOUNTANTS**

**Anuradha Ratnaparkhi**

M.com., FCA



9D, Sampat Farms, Survey No. 15/26,  
Opp. Agrawal Public School,  
Bicholi Mardana Road, Indore 452 016 (M.P.)  
Tel. : +91 731-4979244, M : +91 98934-62644  
E-mail : associate@caanuradha.co.in

**Annexure 1**

List of entities included in the statement:

I) Subsidiary:

1. Norfolk Mercantile Private Limited

